2009
DOI: 10.1007/s10544-009-9376-7
|View full text |Cite
|
Sign up to set email alerts
|

Estimating design space available for polyepitopes through consideration of major histocompatibility complex binding motifs

Abstract: Major histocompatibility complex (MHC ) epitope presentation is needed for robust adaptive immune responses. Core peptide binding motifs for class I and class II MHC are 8-10 amino acids long, containing two or more "anchor" residues. These binding motifs define epitope anchor amino acid content and spacing, and knowledge of them has facilitated emergence of polyepitope vaccines. However, polyepitopes can exhibit "junctional epitopes" (neoepitopes interfering with vaccine function) resulting from juxtaposition… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
5
0

Year Published

2009
2009
2017
2017

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 9 publications
(5 citation statements)
references
References 39 publications
(77 reference statements)
0
5
0
Order By: Relevance
“…Additional signal sequences (for example, N-terminal ubiquitin, N-terminal leader peptide, and C-terminal fragment of human LAMP-1 protein) could be introduced into target polyepitopes to increase their efficiency of stimulating either CD8+ and/or CD4+ T-cell response [10-14]. However, despite numerous efforts towards constructing artificial polyepitope immunogens and evaluating their immunogenicity and protectivity [2,4-9,15,16] and despite numerous computational methods developed to date for predicting T-cell epitopes [17-20], proteasomal cleavage sites [21-25], and peptide binding to TAP (transporters associated with antigen processing) [24,26-28], only a few computational tools intended for rational design of polyepitope T-cell immunogens were developed to date [29,30]. …”
Section: Resultsmentioning
confidence: 99%
“…Additional signal sequences (for example, N-terminal ubiquitin, N-terminal leader peptide, and C-terminal fragment of human LAMP-1 protein) could be introduced into target polyepitopes to increase their efficiency of stimulating either CD8+ and/or CD4+ T-cell response [10-14]. However, despite numerous efforts towards constructing artificial polyepitope immunogens and evaluating their immunogenicity and protectivity [2,4-9,15,16] and despite numerous computational methods developed to date for predicting T-cell epitopes [17-20], proteasomal cleavage sites [21-25], and peptide binding to TAP (transporters associated with antigen processing) [24,26-28], only a few computational tools intended for rational design of polyepitope T-cell immunogens were developed to date [29,30]. …”
Section: Resultsmentioning
confidence: 99%
“…The functional assay showed that Y 367 mutated peptides (Y 367 A and Y 367 K) could induce IFN-γ responses, but that IFN-γ production was lower than that induced by S366-374. That might indicate an important role for the Y side chain in determining the binding affinity to H-2 K d [10].…”
Section: Discussionmentioning
confidence: 99%
“…The surface features of the binding cleft of the class I MHC molecule are complementary to side chains of the anchor residues in the displayed peptide. The amino acid residues lining the binding sites may vary among different class I allelic variants [9,10]. Here, an SARS CoV S protein CTL epitope, S366-374, was identified and the functions of individual residues were evaluated by bioinformatics tool prediction and by IFN-γ responses induced by a series of modified S366-374 peptides.…”
Section: Introductionmentioning
confidence: 99%
“…A commonly reported peptidic spacer for genetic constructs is the GPGPG sequence (Livingston et al ., ). The computational algorithm CANVAC II has been developed to aid the design of junctional epitope‐free polyepitopes (Lee et al ., ). Given two authentic epitopes, a target set of MHC‐binding motifs and a range of desired linker lengths, CANVAC predicts spacer sequences with optimal length and composition.…”
Section: Epitope‐based Vaccine Designmentioning
confidence: 99%